Individual data for patients with iTTP before and after the preemptive rituximab treatment
| Identification . | Delay between preemptive rituximab and sample . | ADAMTS13 activity (FRET S-VWF73), % . | Anti-ADAMTS13 IgG, IU/mL . | ADAMTS13 Ag, µg/mL . | Conformation index . |
|---|---|---|---|---|---|
| A-01 | Before | <5 | 26 | 0.44 | 3.8 |
| R-01 | 2 months | 84 | 7 | 0.78 | 0.3 |
| A-02 | Before | <5 | 27 | 0.49 | 3.1 |
| R-02 | 2 months | 80 | 8 | 0.88 | 0.3 |
| A-03 | Before | <5 | 27 | 0.26 | 5.5 |
| R-03 | 1 month | 86 | 10 | 1.00 | 0.2 |
| A-04 | Before | <5 | 12 | 0.22 | 8.9 |
| R-04 | 3 months | 89 | 6 | 1.06 | 0.8 |
| A-05 | Before | <5 | 61 | 0.23 | 3.8 |
| R-05 | 2 months | 67 | 9 | 1.2 | 0.5 |
| A-06 | Before | <5 | 15 | 0.58 | 3.4 |
| R-06 | 2 months | 77 | 10 | 1.07 | 0.7 |
| A-07 | Before | <5 | 36 | 0.34 | 2.7 |
| R-07 | 2 months | <10 | 61 | 0.48 | 2.7 |
| A-08 | Before | <5 | 23 | 0.69 | 1.9 |
| R-08 | 2 months | 25 | 48 | 0.79 | 1.2 |
| Identification . | Delay between preemptive rituximab and sample . | ADAMTS13 activity (FRET S-VWF73), % . | Anti-ADAMTS13 IgG, IU/mL . | ADAMTS13 Ag, µg/mL . | Conformation index . |
|---|---|---|---|---|---|
| A-01 | Before | <5 | 26 | 0.44 | 3.8 |
| R-01 | 2 months | 84 | 7 | 0.78 | 0.3 |
| A-02 | Before | <5 | 27 | 0.49 | 3.1 |
| R-02 | 2 months | 80 | 8 | 0.88 | 0.3 |
| A-03 | Before | <5 | 27 | 0.26 | 5.5 |
| R-03 | 1 month | 86 | 10 | 1.00 | 0.2 |
| A-04 | Before | <5 | 12 | 0.22 | 8.9 |
| R-04 | 3 months | 89 | 6 | 1.06 | 0.8 |
| A-05 | Before | <5 | 61 | 0.23 | 3.8 |
| R-05 | 2 months | 67 | 9 | 1.2 | 0.5 |
| A-06 | Before | <5 | 15 | 0.58 | 3.4 |
| R-06 | 2 months | 77 | 10 | 1.07 | 0.7 |
| A-07 | Before | <5 | 36 | 0.34 | 2.7 |
| R-07 | 2 months | <10 | 61 | 0.48 | 2.7 |
| A-08 | Before | <5 | 23 | 0.69 | 1.9 |
| R-08 | 2 months | 25 | 48 | 0.79 | 1.2 |
Patient identification, interval in months between preemptive rituximab treatment and blood sampling, ADAMTS13 activity (%), anti-ADAMTS13 antibody titers (IU/mL), and conformation index are given for 8 matched iTTP patient samples before (“A”) and after (“R”) preemptive rituximab treatment. Conformation index >0.5 indicates an open ADAMTS13 conformation.
Ag, antigen; IgG, immunoglobulin G.